In vivo effects of rosiglitazone in a human neuroblastoma xenograft

British Journal of Cancer

Volumn 102, Issue 4, 2010, Pages 685-692

  Cellai, I ^a   Petrangolini, G ^b   Tortoreto, M ^b   Pratesi, G ^b   Luciani, P ^a   Deledda, C ^a   Benvenuti, S ^a   Ricordati, C ^c   Gelmini, S ^a   Ceni, E ^a   Galli, A ^a   Balzi, M ^a   Faraoni, P ^a   Serio, M ^a   Peri, A ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

NB; PPARg ; RGZ; Xenograft

Indexed keywords

CASPASE 3; CD31 ANTIGEN; GELATINASE B; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SIZE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FEEDING; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; PPAR GAMMA; THIAZOLIDINEDIONES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76949097474     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605506     Document Type: Article

References (73)

1. Annicotte JS, Iankova I, Miard S, Fritz V, Sarruf D, Abella A, Berthe ML, Noël D, Pillon A, Iborra F, Dubus P, Maudelonde T, Culine S, Fajas L (2006) Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 26: 7561-7574
2. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloprotei-nase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744
3. Bernini GP, Moretti A, Viacava P, Bonadio AG, Iacconi P, Miccoli P, Salvetti A (2002) Apoptosis control and proliferation marker in human normal and neoplastic adrenocortical tissues. Br J Cancer 86: 1561-1565
4. Bogazzi F, Ultimieri F, Raggi F, Russo D, Vanacore R, Guida C, Viacava P, Cecchetti D, Acerbi G, Brogioni S, Cosci C, Gasperi M, Bartalena L, Martino E (2004) PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocri-nol 150: 863-875
5. Burstein HG, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP (2003) Use of peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatement for refractory breast cancer: a phase II study. Breast Cancer Res Treat 79: 391-397
6. Cellai I, Benvenuti S, Luciani P, Galli A, Ceni E, Simi L, Baglioni S, Muratori M, Ottanelli B, Serio M, Thiele CJ, Peri A (2006) Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells. Br J Cancer 95: 879-888
7. Cesario RM, Stone J, Yen WC, Bissonnette RP, Lamph WW (2006) Differentiation and growth inhibition mediated via the RXR: PPARgamma heterodimer in colon cancer. Cancer Lett 240: 225-233
8. Chantrain CF, Shimada H, Jodele S, Groshen S, Ye W, Shalinsky DR, Werb Z, Coussens LM, DeClerck YA (2004) Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 64: 1675-1686
9. Chattopadhyay N, Singh DP, Heese O, Godbole MM, Sinohara T, Black PM, Brown EM (2000) Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis. J Neurosci Res 61: 67-74
10. Cioppi F, Simi L, Luciani P, Petraglia F, Susini T, Cobellis L, Serio M, Maggi M, Peri A (2004) Expression of uteroglobin and matrix metalloproteinase-9 genes in endometrial cancer: relationship to estrogen and progesterone receptor status. Oncol Rep 11: 427-433
11. De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero Di Montezemolo L, Donfrancesco A, Pession A, Provenzi M, di Cataldo A, Rizzo A, Tonini GP, Dallorso S, Conte M, Gambini C, Garaventa A, Bonetti F, Zanazzo A, D'Angelo P, Bruzzi P (2003) Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 21: 1592-1601
12. Debrock G, Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R, Van Oosterom A (2003) A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 89: 1409-1412
13. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S (1999) Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-g ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 96: 3951-3956
14. Desvergne B, Whali W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Rev 20: 649-688
15. Emmans VC, Rodway HA, Hunt AN, Lillycrop KA (2004) Regulation of cellular processes by PPARgamma ligands in neuroblastoma cells is modulated by the level of retinoblastoma protein expression. Biochem Soc Trans 32: 840-842
16. Galli A, Mello T, Ceni E, Surrenti E, Surrenti C (2006) The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin Investig Drugs 15: 1039-1049
17. Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR, Boni L, Ponzoni M, Decensi A, De Bernardi B, Bellani FF, Formelli F (2003) Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9: 2032-2039
18. Grommes C, Landreth GE, Heneka MT (2004) Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 5: 419-429
19. Han SW, Greene ME, Pitts J, Wada RK, Sidell N (2001) Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells. Clin Cancer Res 7: 98-104
20. Hazra S, Peebles KA, Sharma S, Mao JT, Dubinett SM (2008) The role of PPARgamma in the cyclooxygenase pathway in lung cancer. PPAR Res 2008: 790568
21. Heaney AP, Fernando M, Yong WH, Melmed S (2002) Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8: 1281-1287
22. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, Crystal RG, Besmer P, Lyden D, Moore MA, Werb Z, Rafii S (2002) Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109: 625-637
23. Hisatake J, Ikezoe T, Carey Y, Holden S, Tomoyasu S, Koeffler HP (2000) Down regulation of prostate-specific antigen expression by ligands for peroxisome-activator receptor gamma in human prostate cancer. Cancer Res 60: 5494-5498
24. Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: a comparation between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580
25. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86
26. Joshi VV, Tsongalis GJ (1997) Correlation between morphologic and nonmorphologic prognostic markers of neuroblastoma. Ann N Y Acad Sci 824: 71-83
27. Jude-Aubry C, Pernin A, Favez T, Burger AG, Wahli W, Meier CA, Desvergne B (1997) DNA binding properties of peroxisome proliferator activated receptor subtypes on various natural peroxisome proliferator response elements. J Biol Chem 272: 25252-25259
28. Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S, Kamat AM (2006) Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p- substitutedphenyl) methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res 66: 412-418
29. Kato M, Nagaya T, Fujieda M, Saito K, Yoshida J, Seo H (2002) Expression of PPARg and its ligand-dependent growth inhibition in human brain tumor cell lines. Jpn J Cancer Res 93: 660-666
30. Katoh M, Feldhaus S, Schnitzer T, Bauer S, Schumacher U (2004) Limited tumor growth (HT29) in vivo under RO205-2349 is due to increased apoptosis and reduced cell volume but not to decreased proliferation rate. Cancer Lett 210: 7-15
31. Kersten S, Desvergne B, Wahli W (2000) Roles of PPARs in health and disease. Nature 405: 421-424
32. Kim EJ, Park KS, Chung SY, Sheen YY, Moon DC, Song YS, Kim KS, Song S, Yun YP, Lee MK, Oh KW, Yoon DY, Hong JT (2003) Peroxisome proliferator-activated receptor-g activator 15-deoxy-D12,14-prostaglan-din J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal regulated kinase signal pathway. J Pharmacol Exp Ther 307: 505-517
33. Koeffler HP (2003) Peroxisome proliferator-activated receptor g and cancers. Clin Cancer Res 9: 1-9
34. Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS (2002) A phase II study of troglitazone, an activator of PPAR gamma receptor, in patients with chemoteraphy-resistant matastatic colorectal cancer. Cancer J 8: 395-399
35. Luciani P, Ferruzzi P, Arnaldi G, Crescioli C, Benvenuti S, Nesi G, Valeri A, Greeve I, Serio M, Mannelli M, Peri A (2004) Expression of the novel adrenocorticotropin-responsive gene selective Alzheimer's disease indicator-1 in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. J Clin Endocrinol Metab 89: 1332-1339
36. Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369: 2106-2120
37. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341: 1165-1173
38. Melino G, Thiele CJ, Knight RA, Piacentini M (1997) Retinoids and the control of growth/death decisions in human neuroblastoma cell lines. J Neurooncol 31: 65-83
39. Morosetti R, Servidei T, Mirabella M, Rutella S, Mangiola A, Maira G, Mastrangelo R, Koeffler HP (2004) The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. Int J Oncol 25: 493-502
40. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW (2000) Effects of ligand activation of peroxisome proliferators-activated receptor g in human prostate cancer. Procl Natl Acad Sci USA 97: 10990-10995
41. National Cancer Institute, Surveillance, Epidemiology and End Results Database. Available at http://seer.cancer.gov Accessed on November, 2005
42. Nemenoff RA (2007) Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus 'off-target' effectors. J Thorac Oncol 2: 989-992
43. Nwankwo JO, Robbins ME (2001) Peroxisome proliferator-activated receptor gamma expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins Leukot Essent Fatty Acids 64: 241-245
44. O'Donovan N, Crown J, Stunnel H, Hill AD, McDermott E, O'Higgins N, Duffy MJ (2003) Caspase 3 in breast cancer. Clin Cancer Res 9: 738-742
45. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA (2001) Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gand mediated by inhibition of translation initiation. Cancer Res 61: 6213-6218
46. Peri A, Cellai I, Benvenuti S, Luciani P, Baglioni S, Serio M (2008) PPARgamma in neuroblastoma. PPAR Res 2008: 917815
47. Pratesi G, Pezzoni G, Parmiani G (1985) NMU-1, a new transplantable mouse lung tumor: biological and chemosensitivity properties in vivo. Cancer Treat Rep 69: 219-221
48. Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, Lazar MA (1998) A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor g-activating properties. J Biol Chem 273: 32679-32684
49. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ (2003) Retinoid therapy of high-risk neuroblastoma. Cancer Lett 197: 185-192
50. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK (1998) Expression of the peroxisome proliferator-activated receptor gamma (PPAR gamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density protein. Procl Natl Acad Sci USA 95: 7614-7619
51. Rohn TT, Wong SM, Cotman CW, Cribbs DH (2001) 15-deoxy-D12,14- prostaglandin J2, a specific ligand for peroxisome proliferator-activated receptor-g, induces neuronal apoptosis. Neuroreport 12: 839-843
52. Roman J (2008) Peroxisome proliferator-activated receptor gamma and lung cancer biology: implications for therapy. J Investig Med 56: 528-533
53. Saltiel AR, Olefsky JM (1996) Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45: 1661-1669
54. Schultze K, Böck B, Eckert A, Oevermann L, Ramacher D, Wiestler O, Roth W (2006) Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis 11: 1503-1512
55. Servidei T, Morosetti R, Ferlini C, Cusano G, Scambia G, Mastrangelo R, Koeffler HP (2004) The cellular response to PPARgamma ligands is related to phenotype of neuroblastomi cell lines. Oncol Res 14: 345-354
56. Shao D, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ, Lazar MA (1998) Interdomain communication regulating ligand binding by PPAR-gamma. Nature 396: 377-380
57. Shimazaki N, Togashi N, Hanai M, Isoyama T, Wada K, Fujita T, Fujiwara K, Kurakata S (2008) Anti-tumor activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidi-nedione class, in human tumor xenografts and a syngeneic tumour implant model. Eur J Cancer 44: 1734-1743
58. Spiegelman BM (1998) PPAR-gamma: adipogenic regulator and thiazoli-dinedione receptor. Diabetes 47: 507-514
59. Stojadinovic A, Brennan MF, Hoos A, Omeroglu A, Leung DH, Dudas ME, Nissan A, Cordon-Cardo C, Ghossein RA (2003) Adrenocortical adenoma and carcinoma: histopathological and molecular comparative analysis. Mod Pathol 16: 742-751
60. Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ, Lahti JM, Cheresh DA (2006) Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 439: 95-99
61. Sugiura Y, Shimada H, Seeger RC, Laug WE, DeClerck YA (1998) Matrix metalloproteinases-2 and-9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res 58: 2209-2216
62. Tontonoz P, Kim JB, Graves RA, Spiegelman BM (1993) ADD1: a novel helix-loop-helix transcription factor associated with adipocytes determination and differentiation. Mol Cell Biol 13: 4753-4759
63. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, Inoue K, Hla T, Kondo M (2000) Inhibition of human lung cancer-cell growth by peroxisome proliferators-activated receptor gamma agonist through induction of apoptosis. Biochem Biophys Res Commun 270: 400-405
64. Vakkala M, Pääkö P, Soini Y (1999) Expression of caspases 3, 6, and 8 is increased in parallel with apoptosis and histological aggressiveness of the breast lesion. Br J Cancer 81: 592-599
65. Valentiner U, Carlsson L, Erttmann RM, Hildebrandt H, Shumacher U (2005) Ligands for peroxisome proliferator-activated receptor-g have inhibitory effects on growth of human neuroblastoma cells in vitro. Toxicology 213: 157-168
66. Vecchi A, Garlanda C, Lampugnani MG, Resnati M, Matteucci C, Stoppacciaro A, Schnurch H, Risau W, Ruco L, Mantovani A (1994) Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur J CellBiol 63: 247-254
67. Voigt A, Zintl F (2003) Effects of retinoic acid on proliferation, apoptosis, citotoxicity migration, and invasion of neuroblastoma cells. Med Pediatr Oncol 40: 205-213
68. Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS (2006) Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 13: 401-413
69. Wong SC, Chan JK, Lee KC, Hsiao WL (2001) Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumor progression in invasive ductal carcinoma of the breast. J Pathol 194: 35-42
70. Workman P, Balmain A, Hickman JA, McNally NJ, Rohas AM, Mitchison NA, Pierrepoint CG, Raymond R, Rowlatt C, Stephens TC (1988) UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim 22: 195-201 (Pubitemid 18192895)
71. Xin B, Yokoyama Y, Shigeto T, Futagami M, Mizunuma H (2007) Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. Cancer 110: 791-800
72. Yki-Järvinen H (2004) Thiazolidinediones. N Engl J Med 351: 1016-1018
73. Yoshizumi T, Ohta T, Ninomiya I, Terada I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Yi S, Miwa K (2004) Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol 25: 631-639